Recognizing and Managing AEs in NSCLC

CE / CME

Fundamentals III: Recognizing and Managing AEs and Addressing Adherence and Barriers

Nurse Practitioners: 0.75 Nursing contact hours, includes 0.75 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Released: November 12, 2024

Expiration: May 11, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following has been the most common AE associated with dato-DXd reported in patients with advanced recurrent NSCLC?

2.

Which of the following is part of the guidelines for the management of grade 1/2 mucositis with datopotamab deruxtecan?